These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6218567)

  • 1. Activity, stability, and pharmacology of the epimers of moxalactam.
    Wise R; Wright N; Wills PJ
    Rev Infect Dis; 1982; 4 Suppl():S564-8. PubMed ID: 6218567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epimers of moxalactam: in vitro comparison of activity and stability.
    Wise R; Wills PJ; Bedford KA
    Antimicrob Agents Chemother; 1981 Jul; 20(1):30-2. PubMed ID: 6456687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam epimer kinetics in children.
    Nahata MC; Durrell DE; Barson WJ
    Clin Pharmacol Ther; 1982 Apr; 31(4):528-32. PubMed ID: 6460588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state moxalactam kinetics: comparisons with other cephalosporins.
    Garzone P; Lyon J; Yu VL; Zuravleff J; Diven W; Pasculle W
    Clin Pharmacol Ther; 1981 Jul; 30(1):86-94. PubMed ID: 6453677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Antimicrob Agents Chemother; 1981 Nov; 20(5):567-75. PubMed ID: 6275776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.
    Yoshida T; Matsuura S; Mayama M; Kameda Y; Kuwahara S
    Antimicrob Agents Chemother; 1980 Mar; 17(3):302-12. PubMed ID: 6448572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of moxalactam in patients with renal insufficiency.
    Lam M; Manion CV; Czerwinski AW
    Antimicrob Agents Chemother; 1981 Mar; 19(3):461-4. PubMed ID: 6454383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
    Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam: the first of a new class of beta-lactam antibiotics.
    Webber JA; Yoshida T
    Rev Infect Dis; 1982; 4 Suppl():S496-500. PubMed ID: 6218558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antibacterial activity of moxalactam, an oxa-beta-lactam antibiotic.
    Goto S
    Rev Infect Dis; 1982; 4 Suppl():S501-10. PubMed ID: 6218559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of moxalactam in renal failure.
    Wright N; Wills PJ; Wise R
    J Antimicrob Chemother; 1981 Nov; 8(5):395-9. PubMed ID: 6459316
    [No Abstract]   [Full Text] [Related]  

  • 14. Quality control of moxalactam susceptibility disks.
    Barry AL; Preston DA; Jones RN; Gavan TL; Thornsberry C
    J Clin Microbiol; 1983 Jun; 17(6):1032-8. PubMed ID: 6223936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro comparison of cefotetan with five other cephalosporins against nosocomial pathogens.
    Daschner FD; Goerke C; Bassler M; Just M
    Chemotherapy; 1982; 28(5):351-4. PubMed ID: 6958416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity and beta-lactamase stability of moxalactam and other selected cephalosporin antibiotics.
    Vuye A
    Arzneimittelforschung; 1981; 31(8):1290-5. PubMed ID: 6457607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
    Bolton WK; Scheld WM; Spyker DA; Overby TL; Sande MA
    Antimicrob Agents Chemother; 1980 Dec; 18(6):933-8. PubMed ID: 6453555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of the novel oxa-beta-lactam antibiotic moxalactam (LY 127935) against dense populations of selected Gram-negative bacilli.
    Greenwood D; Eley A; Pearson N; O'Grady F
    J Antimicrob Chemother; 1981 Apr; 7(4):353-62. PubMed ID: 6265424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro action of moxalactam on hospital bacteria. Results of a multicenter survey].
    Duval J; Deforges L; Bergogne-Berezin E; Chabbert YA; Courtieu AL; Cluzel R; Dabernat H; Witchitz JL
    Sem Hop; 1983 Jun; 59(26):1949-52. PubMed ID: 6310784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.